Paysign Inc (PAYS)
🔔 Watch stock
Appears in These Scanners
This stock currently matches 13 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Quality & Screener
AI Rating
NeutralIn den letzten 4 Quartalsberichten und 2 Jahresberichten von PaySign findet sich kein wesentlicher KI-Bezug — die einzige Erwähnung von „artificial intelligence“ ist ein generischer Risikofaktor in beiden 10-Ks („Our ability to adapt our existing products and services to use artificial intelligence (‚AI‘) could adversely impact our business“ — es geht dort um regulatorische Unsicherheit rund um KI-Gesetze, nicht um eine konkrete Disruptionsgefahr für das Prepaid-/Payment-Geschäft), die vier 10-Qs enthalten gar keine KI-Erwähnung; weder KI-Umsatzquelle noch belegter operativer Einsatz noch konkretes Geschäftsrisiko.
View the full file — quotes, sources, reviewed filings
Filings Reviewed: 10-Q 2026-05-13 · 10-Q 2025-11-13 · 10-Q 2025-08-06 · 10-Q 2025-05-09 · 10-K 2026-03-25 · 10-K 2025-03-26
Rated on July 9, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2023: Q2 | 0.00 | – | 11 | 27.90 | -0.90 | -3 | -5 |
| 2023: Q3 | 0.02 | 0.00 | 12 | 17.00 | 8.90 | 4 | 2 |
| 2023: Q4 | 0.10 | 900.00 | 14 | 29.20 | 40.90 | 23 | 21 |
| 2024: Q1 | 0.01 | – | 13 | 30.70 | 2.30 | 8 | 6 |
| 2024: Q2 | 0.01 | – | 14 | 30.00 | 4.90 | 21 | 18 |
| 2024: Q3 | 0.03 | 50.00 | 15 | 23.40 | 9.20 | -20 | -23 |
| 2024: Q4 | 0.02 | -76.40 | 16 | 14.00 | 8.80 | 14 | 12 |
| 2025: Q1 | 0.05 | 731.10 | 19 | 41.00 | 13.90 | -6 | -9 |
| 2025: Q2 | 0.02 | 92.20 | 19 | 33.10 | 7.30 | 4 | 2 |
| 2025: Q3 | 0.04 | 39.90 | 22 | 41.60 | 10.30 | 7 | 5 |
| 2025: Q4 | 0.02 | -10.50 | 23 | 45.80 | 6.00 | 48 | 46 |
| 2026: Q1 | 0.09 | 90.10 | 28 | 50.80 | 19.40 | 19 | 17 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Paysign, Inc. bietet Prepaid-Kartenprogramme, Patientenkostenlösungen, Digital Banking, Life-Science-Softwaretechnologielösungen und integrierte Zahlungsabwicklungsdienstleistungen für Unternehmen, Verbraucher und staatliche Einrichtungen in den USA an.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 226 |
| Headquarters | Henderson, NV |
| Website | paysign.com |
| IPO Date | 2. Apr 1998 |
| Next Earnings | 4. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Mark R. Newcomer | Co-Founder, President, CEO & Director | 1965 |
| Matthew Turner | President of Patient Affordability | – |
| Michael Ngo | Chief Innovation Officer | – |
| Jeffery B. Baker | CFO & Treasurer | 1972 |
| Cosimo Cambi | Chief Operating Officer | – |
| Brad Cunningham | Chief Technology Officer | – |
| Eric Trudeau | Chief Compliance Officer | – |
| Robert P. Strobo Esq. | General Counsel, Chief Legal Officer & Corporate Secretary | 1980 |
| Dennis M. DiVenuta J.D. | Executive Vice President of Strategy & Corporate Development | – |
| Alicia Ches | Vice President of Marketing | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.